Skip to main content
SpringerLink
Log in

Management of the Suprapontine Neurogenic Lower Urinary Tract Dysfunction

  • Chapter
  • First Online:
Suprapontine Lesions and Neurogenic Pelvic Dysfunctions

Part of the book series: Urodynamics, Neurourology and Pelvic Floor Dysfunctions ((UNPFD))

  • 388 Accesses

Abstract

In the case of suprapontine lesions, the most common bladder dysfunction is neurogenic detrusor overactivity. Antimuscarinics can be considered the mainstay of treatment, while other therapies like cannabinoids look promising. Intravesical injection of botulinum toxin can be considered the main second-line treatment in case of failure of antimuscarinics. Conservative treatments should be associated with drugs. Cognitive effects of therapy shall be bared in mind for all the therapies with systemic absorption.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Powell CR. Not all neurogenic bladders are the same: a proposal for a new neurogenic bladder classification system. Transl Androl Urol. 2016;5:12–21.

    PubMed  PubMed Central  Google Scholar 

  2. Griffiths D. In: Vodusek DB, editor. Functional imaging of structures involved in the neural control of the LUT. Amsterdam: Elsevier; 2015.

    Google Scholar 

  3. De Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol. 2015;5:327–96.

    PubMed  PubMed Central  Google Scholar 

  4. Sakakibara R. In: Vodusek DB, editor. Lower urinary tract dysfunction in patients with brain lesions. 1st ed. Amsterdam: Elsevier; 2015.

    Google Scholar 

  5. Mehnert U. Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology and treatment options. Urologe. 2012;51:189–97.

    Article  CAS  Google Scholar 

  6. Panicker JN. Lower urinary tract symptoms following neurological illness may be influenced by multiple factors: observations from a neurorehabilitation service in a developing country. Neurourol Urodyn. 2010;29:378–81.

    PubMed  Google Scholar 

  7. Nicholas RS. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009:CD004193.

    Google Scholar 

  8. Bennett N. Can higher doses of oxybutynin improve efficacy in the neurogenic bladder? J Urol. 2004;171:749–51.

    Article  CAS  PubMed  Google Scholar 

  9. Stohrer M. Propiverine compared to oxybutynin in neurogenic detrusor overactivity: results of a randomised, double-blind, multicenter clinical study. Eur Urol. 2007;51:235–42.

    Article  PubMed  CAS  Google Scholar 

  10. Zasiewics TA. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:14–20.

    Google Scholar 

  11. Amend B. Effective treatment of neurogenic detrusor dysfunction by combined high dosed antimuscarinics without increased side effects. Eur Urol. 2008;53:1021–8.

    Article  CAS  PubMed  Google Scholar 

  12. Sakakibara R. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc. 2009;57:1515–7.

    Article  PubMed  Google Scholar 

  13. Wollner J. Initial experience with the treatment of neurogenic detrusor overactivity with a new beta-3 agonist (Mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78–82.

    Article  CAS  PubMed  Google Scholar 

  14. Chen SF. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Low Urin Tract Symptoms. 2018;5:1–6.

    Google Scholar 

  15. Brady CM. An open-label study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10:425–33.

    Article  CAS  PubMed  Google Scholar 

  16. Freeman RM. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicenter, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:636–41.

    Article  CAS  PubMed  Google Scholar 

  17. Strittmatter F. Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. Eur Urol. 2012;61:98–106.

    Article  CAS  PubMed  Google Scholar 

  18. Aizawa N. Inhibition of peripheral FAAH depresses activities of bladder mechanosensitive nerve fibers of the rat. J Urol. 2014;192:956–63.

    Article  CAS  PubMed  Google Scholar 

  19. Cruz F. Efficacy and safety of continence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:472–50.

    Article  CAS  Google Scholar 

  20. Herschorn S. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomised, double blind trial. J Urol. 2011;185:2229–35.

    Article  CAS  PubMed  Google Scholar 

  21. Ginsberg D. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9.

    Article  CAS  PubMed  Google Scholar 

  22. Del Popolo G. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol. 2008;53:1013–20.

    Article  PubMed  CAS  Google Scholar 

  23. De Laet K. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord. 2005;43:397–9.

    Article  PubMed  Google Scholar 

  24. Groen J, Pannek J, Castro Diaz D, et al. Summary of European association of urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69:324–33.

    Article  PubMed  Google Scholar 

  25. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14:720–32.

    Article  PubMed  Google Scholar 

  26. McGuire E, Zhang S, Horwinski E, Lytton B. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol. 1983;129(1):78–9.

    Article  CAS  PubMed  Google Scholar 

  27. Finazzi-Agrò E, Rocchi C, Pachats C, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28(4):320–4.

    Article  PubMed  Google Scholar 

  28. Stoller M. Afferent nerve stimulation for pelvic floor dysfunction. Eur Urol. 1999;35(Suppl 2):16.

    Google Scholar 

  29. Ramírez-García I, Blanco-Ratto L, Kauffmann S, et al. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: randomised control trial. Neurourol Urodyn. 2018;37:1–8.

    Google Scholar 

  30. Chang P. Urodynamic studies in acupuncture for women with frequency, urgency and dysuria. J Urol. 1988;140(3):563–6.

    Article  CAS  PubMed  Google Scholar 

  31. Yang L, Wang Y, Mo Q. A comparative study of electroacupunture at Zhongliao (BL33) and other acupoint for overactive bladder symptoms. Front Med. 2017;11(1):129–36.

    Article  PubMed  Google Scholar 

  32. MacDiarmid SA, Staskin DR. Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. Curr Bladder Dysfunct Rep. 2009;4(1):29–33.

    Article  Google Scholar 

  33. Matthew R, Cooperberg T, Stoller ML. Percutaneous neuromodulation. Urol Clin N Am. 2005;32:71–8.

    Article  Google Scholar 

  34. Finazzi A, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Nefrol. 2005;57:119–23.

    Google Scholar 

  35. Martin-Garcia M, Crampton J. A single-blind, randomised controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in overactive bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). Physiotherapy. 2018; https://doi.org/10.1016/j.physio.2018.12.002.

    Article  PubMed  Google Scholar 

  36. Vecchioli-Scaldazza C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomised controlled study with a follow-up of ten months. Int Braz J Urol. 2018;44:102–8.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Heesakkers J, Digesu G, van Breda J, et al. A novel leadless, miniature implantable Tibial nerve neuromodulation system for the management of overactive bladder complaints. Neurourol Urodyn. 2018;37:1060–7.

    Article  PubMed  Google Scholar 

  38. MacDiarmid S, Lucente V, Kaaki B, et al. Safety & efficacy of the eCoin™ implantable tibial nerve stimulation device for overactive bladder syndrome: UroToday. p. MP75–18.

    Google Scholar 

  39. Van Balken M, Vergunst H, Bemelmans B. The use of electrical devices for the treatment of bladder dysfunction: a review of methods. J Urol. 2004;172:846–51.

    Article  PubMed  Google Scholar 

  40. Yoong W, Ridout AE, Damodaram M, et al. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int. 2010;106:1673–6.

    Article  PubMed  Google Scholar 

  41. Sundin T, Carlsson CA, Kock NG. Detrusor inhibition induced from mechanical stimulation of the anal region and from electrical stimulation of pudendal nerve afferents. An experimental study in cats. Investig Urol. 1974;11:374–8.

    CAS  Google Scholar 

  42. Gross T, Schneider M, Bachmann L, et al. Transcutaneous electrical nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. Eur Urol. 2016;69:1102–11.

    Article  PubMed  Google Scholar 

  43. Amarenco G, Ismael SS, Even-Schneider A, et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003;169:2210–5.

    Article  CAS  PubMed  Google Scholar 

  44. Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat. Rev Urol. 2016 May;13(5):275–88. https://doi.org/10.1038/nrurol.2016.53.

    Article  CAS  Google Scholar 

  45. Canbaz Kabay S, Kabay S, Mestan E, Cetiner M, Ayas S, Sevim M, Ozden H, Karaman HO. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2017;36(1):104–10.

    Article  PubMed  Google Scholar 

  46. Kabay S, Canbaz Kabay S, Cetiner M, et al. The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients With Parkinson’s Disease. Urology. 2016;87:76–81.

    Article  PubMed  Google Scholar 

  47. Finazzi-Agrò E, Rocchi C, Pachats C, et al. Percutaneous Tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28(4):320–4.

    Article  PubMed  Google Scholar 

  48. Vahr S, Cobussen-Boekhorst H, Eikenboom J, Geng V, et al. Evidence-based guidelines for best practice in urological health care. Catheterisation urethral intermittent catheterisation in adults. Revised by Biroli A, Gibertini G. Fondazione Italiana Continenza, 2018.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology and Andrology Unit II, University of Bari, Bari, Italy

    Gaetano De Rienzo

  2. Neurorehabilitation Unit and Pelvic Floor Dysfunction Rehabilitation Center, SS Trinità Hospital, Cuneo, Italy

    Gianfranco Lamberti

  3. UOC MFR and Unipolar Spinal Unit, Polyclinic Consortium Hospital of Bari, Bari, Italy

    Luisa De Palma

  4. Urology Department, San Raffaele Turro Hospital, Milan, Italy

    Donatella Giraudo

  5. Neuro-Urology Unit, CTO - Spinal Unit, Città della Salute e della Scienza di Torino, Turin, Italy

    Elena Bertolucci & Giuseppina Gibertini

  6. University of Rome Tor Vergata, Rome, Italy

    Caterina Gruosso

  7. ASST dei Sette Laghi, Hospital “Del Ponte”, Varese, Italy

    Roberta Robol

Authors
  1. Gaetano De Rienzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianfranco Lamberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luisa De Palma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Donatella Giraudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Bertolucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuseppina Gibertini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caterina Gruosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberta Robol
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurorehabilitation Unit and Pelvic Floor Dysfunction Rehabilitation Center, SS Trinità Hospital, Cuneo, Italy

    Gianfranco Lamberti

  2. Urology Department, San Raffaele Hospital, Milano, Italy

    Donatella Giraudo

  3. Department of Neurourology, Careggi University Hospital, Florence, Italy

    Stefania Musco

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Rienzo, G. et al. (2020). Management of the Suprapontine Neurogenic Lower Urinary Tract Dysfunction. In: Lamberti, G., Giraudo, D., Musco, S. (eds) Suprapontine Lesions and Neurogenic Pelvic Dysfunctions. Urodynamics, Neurourology and Pelvic Floor Dysfunctions. Springer, Cham. https://doi.org/10.1007/978-3-030-29775-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-29775-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-29774-9

  • Online ISBN: 978-3-030-29775-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation